SDN-1009

SDN-1009 is a preclinical **glycoconjugate immunostimulator** being developed by **Sidanis Pharma** as a **host defense modifier** for the prevention or treatment of **bacterial infections** and **fungal infections**. Rather than acting as a conventional direct-acting antimicrobial, it is designed to **augment innate immune responses** against a broad range of microorganisms, including Gram-positive and Gram-negative bacteria as well as fungi. Available company and contextual information describe SDN-1009 as part of Sidanis Pharma's GCI platform, with evidence of protective activity in preclinical infection models after single-dose administration, but without any publicly disclosed specific molecular target or human clinical-stage data.

Other names

glycoconjugate immunostimulatorhost defense modifierimmunostimulator